AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
Status:
Enrolling by invitation
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to
receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice
a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and
prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with
previously untreated peripheral T-cell lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital